Farrar, Gill
Molinuevo, José Luis
Zanette, Michelle
Funding for this research was provided by:
GE Heathcare
Article History
Received: 16 August 2018
Accepted: 4 February 2019
First Online: 13 March 2019
Compliance with ethical standards
:
: Gill Farrar and Michelle Zanette are employees of GE Healthcare. José Luis Molinuevo receives doses of [<sup>18</sup>F]flutemetamol for the ALFA project, a research platform to identify early pathophysiological features of Alzheimer’s Disease (ClinicalTrials.gov identifier NCT02685969; ExternalRef removed).
: The data described in this article were obtained post-hoc from the clinical studies described in references [CitationRef removed], [CitationRef removed] and [CitationRef removed].The study was conducted in accordance with the principles of the Declaration of Helsinki, the Good Clinical Practise: Consolidated Guideline approved by the International Conference on Harmonisation, and applicable national and local laws and regulations.Institutional Review Board/Ethics approval was obtained prior to study initiation, and all participants or their legal representatives provided prior written informed consent including agreement to publish subject to anonymization.The following Institutional review boards or ethics committees approved the study protocol for references [CitationRef removed] and [CitationRef removed] before initiation: Compass Research; Galiz Research; Las Vegas Radiology; Premier Research Institute; Banner Sun Health Research Institute; Mt. Sinai Medical Center; Wien Center for Alzheimer’s Disease; Warren Alpert Medical School of Brown University; Banner Alzheimer’s Institute; University of Michigan; Moorgreen Hospital; VERITAS Research; St Margaret’s Hospital; Miami Jewish Health Systems; Memory Enhancement Center; Oxford Radcliffe Hospitals; Michigan State University; Exodon LLC; and Barrows Neurological Institute (ClinicalTrials.gov identifier NCT01165554).The following Institutional review boards or ethics committees approved the study protocol for reference [CitationRef removed] before initiation: Western Institutional Review Board; Johns Hopkins University School of Medicine Institutional Review Board; Michigan State University Biomedical and Health Institutional Review Board; Hammersmith, Queen Charlotte’s & Chelsea Research Ethics Committee; Mount Sinai Medical Center Institutional Review Board; University of Michigan Medical School Institutional Review Board; De Videnskabsetiske komiteer I region Hovedstaden; Commission d’ethique bio-medicale hospitalofacultaire; Regionala Etikprovningsnamnden I Lund; STM/ETENE, TUKIJA; Comite d’ethique hospito-facultaire de l’Universite de Liege, Centre hospitalier universitaire; Catholic Healthcare West/St. Joseph’s Hospital & Medical Center Institutional Review Board; Medical Ethics Committee UZ KU Leuven/Clinical Research; and the University of Pennsylvania Office of Regulatory Affairs (ClinicalTrials.gov identifier NCT01028053).